
Pharmacally
Dermatomyositis
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Dermatomyositis
New Drug ApprovalFDA Approves LISRAYA as First Targeted Oral Therapy for Adults with DermatomyositisThe FDA has approved LISRAYA (brepocitinib) 30 mg once daily for adults with dermatomyositis, introducing the first targeted oral therapy for the rare autoimmune disease.Fact-Checked
Health TidingsPriovant’s Brepocitinib Gains Priority Review After Phase 3 SuccessPhase 3 VALOR results show brepocitinib significantly improves dermatomyositis outcomes over 52 weeks, with rapid efficacy, skin benefits, and reduced corticosteroid use.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.